Alzheimer's disease (AD) is a fatal neurodegenerative disorder that takes about a decade to develop, making early diagnosis possible. Clinically, the diagnosis of AD is complicated, costly, and inaccurate, so it is urgent to fi nd specifi c biomarkers. Due to its multifactorial nature, a panel of biomarkers for the multiple pathologies of AD, such as cerebral amyloidogenesis, neuronal dysfunction, synapse loss, oxidative stress, and infl ammation, are most promising for accurate diagnosis. Highly sensitive and high-throughput proteomic techniques can be applied to develop a panel of novel biomarkers for AD. In this review, we discuss the metabolism and diagnostic performance of the well-established core candidate cerebrospinal fl uid (CSF) biomarkers (β-amyloid, total tau, and hyperphosphorylated tau). Meanwhile, novel promising CSF biomarkers, especially those identifi ed by proteomics, updated in the last fi ve years are also extensively discussed. Furthermore, we provide perspectives on how biomarker discovery for AD is evolving.
Introduction
Alzheimer's disease (AD) is becoming more prevalent due to the increasing population of people aged over 65 [1] .
It is estimated that it will affect 66 million by 2030 and 115 million by 2050 worldwide if no effective therapeutic strategies are found [2] . Clinically, AD is characterized by cognitive impairment, progressive disturbance of daily activities, many neuropsychiatric symptoms, and behavioral deterioration [3] [4] [5] [6] [7] [8] . Pathologically, it is characterized by deposition of extracellular neuritic plaques composed of β-amyloid (Aβ) [9] and intracellular neurofibrillary tangles (NFTs) consisting of a hyperphosphorylated form of the microtubule-associated protein tau [10] [11] [12] . Besides, loss of neurons and synapses is also a pathological hallmark of AD [13] [14] [15] . The worldwide cost of dementia is huge and expected to skyrocket in the next few years. AD may become one of the most marked social, health, and economic challenges in the twenty-fi rst century [16] .
Clinically, the procedure for the diagnosis of AD is diffi cult and complex. Neuropsychological tests, such as the mini-mental state examination, magnetic resonance imaging of hippocampal volume, and clinical assessment, are used to aid in diagnosis. However, a defi nitive diagnosis of AD requires confirmation at autopsy. It is estimated to take 8-10 years or longer before mild cognitive impairment (MCI) develops into AD [17, 18] . Meanwhile, intervention therapies work most effectively in the early stage of AD. Thus, it is urgent and feasible to seek novel specifi c biomarkers to aid in diagnosis and the evaluation of treatments [19] . Surrounding the brain and spinal cord, cerebrospinal fluid (CSF) is an ideal source refl ecting biochemical changes in the brain of the AD patient [20] . Extensive studies have focused on seeking AD biomarkers in CSF.
A comprehensive search of the Web of Science (January 1990 through November 2013) was conducted with the keywords: "Biomarker", "Alzheimer's disease" and "CSF", limited to studies in English. In this literature, the metabolism and performance of the core CSF biomarkers Aβ42, t-tau, and p-tau are reviewed. Also, emerging potential CSF biomarkers updated in last fi ve years are discussed. 
CSF Aβ42 as a Biomarker of AD
Aβ is a hydrophobic peptide of ~4 kDa and 38-42 aminoacids [21] that can aggregate automatically to form neuritic plaques in the brain. The accumulation and deposition of Aβ is regarded as the critical event contributing to the pathological processes of AD [9] . Aβ is a proteolytic cleavage product of amyloid precursor protein (APP) [22, 23] .
APP is a single membrane-spanning protein with three major alternate cleavage sites and can be spliced by three proteases: α-, β-, and γ-secretases [24] . When APP is cleaved by β-secretase, it produces β-secretase-soluble APP (β-sAPP). Then β-sAPP is cleaved by γ-secretase and Aβ is produced. Alternatively, when APP is cleaved sequentially by α-and γ-secretases, Aβ is not produced.
There are two dominant Aβ products, Aβ42 and Aβ40;
Aβ42 has two more hydrophobic amino-acids [25, 26] . This small change enables Aβ42 to aggregate faster than Aβ40 in adequate solutions. Aβ42 is the major component of neuritic plaques, while Aβ40 predominates in the vascular system and CSF [27] [28] [29] [30] .
As the main pathogenic factor in AD, Aβ is a potential biomarker. The change of total Aβ (t-Aβ), Aβ42, and Aβ40
in AD patients at different stages of the disease has been extensively studied. However, a number of studies showed only a minor decrease of CSF t-Aβ in AD patients relative to healthy controls, while some studies found no marked difference between AD patients and the controls [31] [32] [33] . The CSF levels of Aβ40 are not altered or slightly elevated [32] .
Many studies demonstrated that the levels of CSF Aβ42 in AD are decreased compared with controls [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] . CSF Aβ42 can differentiate AD from controls with 89% sensitivity and 90% specificity [51] . Nevertheless, some studies report an increase [52] or no change [53] in the levels of CSF Aβ42. The varying results may be partially ascribed to the different measurement methods in these studies. Alternatively, it may be that the levels of Aβ42 are signifi cantly decreased in early AD and increase at the severe stage of the disease. Since the level of Aβ42 can be used to predict disease progression from MCI to AD [54] , it may be an early biomarker of AD. In addition, as an internal standard, Aβ40 augments the specifi city and sensitivity of Aβ42 [55] .
CSF t-tau and p-tau as Biomarkers of AD
NFTs, predominantly composed of hyperphosphorylated tau, are another pathological hallmark of AD [56] . Tau undergoes abnormal hyperphosphorylation at various sites, such as threonine 181 and 231, and serine 199, 235, 396
and 404 [35] . Due to aberrant phosphorylation, tau is unable to bind and stabilize the microtubules, contributing to neuronal loss [57] .
A number of studies found increased levels of CSF t-tau in AD cases relative to controls [47, [56] [57] [58] [59] [60] [61] [62] [63] [64] . CSF t-tau has a sensitivity of 83% and a specifi city of 90% in discriminating AD from healthy controls [58] . Taking into account that CSF tau is also elevated in other neurological disorders, such as Parkinson's disease (PD) and frontotemporal dementia (FTD), it is essential to augment the specifi city of CSF t-tau as a biomarker for AD.
CSF p-tau correlates well with cognitive decline and is boosted in AD patients compared with normal controls [57] [58] [59] .
This may be attributed to the release of p-tau from degenerating neurons and subsequent diffusion into the CSF. At the same time, increasing p-tau could disturb the balance of binding between tau and microtubules, leading to higher levels of p-tau in the cytosol. This vicious cycle could contribute to neuronal degeneration. P-tau has 68% sensitivity and 73% specificity in differentiating AD from healthy controls, and 80-88% sensitivity and 42-52% specificity in predicting incipient AD in MCI stages [60] .
Hempel et al. verified the accuracy of CSF p-tau231, p-tau181, and p-tau199 in discriminating AD from FTD, Lewy-body dementia, vascular dementia, and healthy controls [61] . The study revealed that each of the three p-tau markers is significantly elevated in AD compared with the other groups, while p-tau231 provides the greatest discrimination between AD and other neurological disorders, and the combination of all three does not augment the discrimination [61, 62] . Similarly, several other studies have revealed that p-tau231 and p-tau199 can discriminate AD from other dementias with sensitivities and specificities in the range of 80-90% [63] [64] [65] . It is worth noting that, as a microtubule-associated protein, hyperphosphorylation of neurofilaments potentially differentiates AD from both normal aging and other dementias [66] . 
Combination of Aβ42, t-tau, and p-tau as
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AD with greater sensitivity and specifi city than each alone.
Mattsson et al. reported that combination of the Aβ42/p-tau ratio with t-tau discriminates incipient AD with a sensitivity of 78-88% and a specificity of 68-76% [60] . Shoji et al. demonstrated that combination of t-tau and Aβ42 has a sensitivity of 69% and a specifi city of 88% in the diagnosis of AD [55] . Shaw et al. revealed that the combination of Aβ42, t-tau, and the number of apolipoprotein E4 alleles discriminates mild AD from MCI and healthy controls with a sensitivity of 98.2% and a specifi city of 89.9% [67] . Mulder et al. revealed that Aβ42, t-tau, and p-tau diagnose AD with a sensitivity of 93.5% and specifi city of 82.7% [68] .
Novel Candidate CSF Biomarkers
Although decreased Aβ42 with elevated t-tau and p-tau in CSF has high sensitivity and specifi city in the diagnosis of AD, great efforts have been invested in discovering novel candidate biomarkers to improve diagnosis. In the past fi ve years, a number of such biomarkers have been identifi ed on the basis of AD pathogenesis, such as cerebral amyloidogenic pathology, neuronal dysfunction, synapse loss, oxidative stress, and infl ammation (Table 1) .
Cerebral Amyloidogenic Pathology
S100A7 S100A7 is involved in immune responses and has been reported to inhibit the production of Aβ42 and Aβ40. The underlying mechanism may be ascribed to the selective enhancement of α-secretase activity. Qin et al.
revealed that the CSF levels of S100A7 in AD patients are markedly higher than healthy controls using a proteomic technique. S100A7 has potential to serve as a biomarker of AD [69] .
Beta-site APP-cleaving enzyme (BACE1) BACE1 is responsible for the free release of Aβ. Ohno et al. found that CSF BACE1 activity and levels are increased in AD brains, suggesting that it may serve as a biomarker [70] .
Another study reported that CSF BACE1 activity is highly correlated with hippocampal atrophy in AD and may refl ect neurotoxic Aβ-related processes [71] .
Aβ40 oligomers and Aβ42
Oligomeric Aβ species may correlate with the onset of disease due to their role in the pathophysiology of AD. Carol et al. showed that, in combination with total Aβ42, Aβ40 oligomers can diagnose AD remarkably with >95% sensitivity and >90% specifi city [72] .
Aβ40
Although Aβ42, t-tau, and p-tau can discriminate AD from controls with high sensitivity and specificity, adding Aβ40 to the core CSF biomarkers boosts this discrimination [73] . Aβ40 is useful in differential diagnosis among FTD, AD, and controls.
Aβ2-42
Aβ2-42 and Aβ1-42 are both reduced in CSF in AD, but Aβ1-42 does not have sufficient specificity to exclude other dementias. Aβ2-42 distinguishes AD from FTD with an accuracy of >85%, indicating that Aβ2-42 is a promising biomarker for differentiating AD from other degenerative diseases [74] .
Lipoprotein receptor 11 (LR11) LR11 is a sorting protein
that suppresses the production of Aβ, indicating that it is associated with the pathogenesis of AD. The levels of LR11 are higher in the CSF of AD patients than in FTD patients and controls, suggesting potential for distinguishing AD from FTD [75] .
Macrophage colony-stimulating factor (M-CSF) A hematopoietic growth factor, M-CSF activates microglial cells and is involved in the phagocytosis of Aβ in the brain.
The CSF levels of M-CSF are lower in AD than in other non-inflammatory neurological diseases. Further, M-CSF can distinguish MCI patients from controls with 73.7% sensitivity and 75.0% specificity, indicating that it is a potential biomarker for MCI [76] .
TNF-α converting enzyme (TACE) and tumor necrosis factor receptors (TNFRs) Genetic deletion of TNFR1
reduces amyloid plaques and Aβ production through BACE1 regulation in an AD mouse model [77] . The CSF levels of TNFR1 and TNFR2 are lower in AD patients than in healthy controls. The activity of TACE and the CSF levels of soluble TNFRs are elevated in MCI relative to AD [77] , suggesting that TACE activity and soluble TNFRs may be biomarkers of AD and MCI.
Synapse Loss
Neuronal pentraxin receptor (NPR) NPR belongs to the neuronal pentraxin family that is dominantly expressed in the central nervous system. Proteins in this family facilitate the uptake of synaptic materials during synapse formation and remodeling. A proteomic study by Yin et al. showed that the increased NPR level in the CSF of AD patients compared with normal controls is higher than that of PD patients, indicating that NPR is a possible marker for distinguishing AD from PD [78] . [79] . Alpha-synuclein enhances the sensitivity and specifi city of t-tau and p-tau in diagnosing AD and improves the prediction of longitudinal cognitive decline.
Kyotorphin (KTP) KTP is an endogenous neuroprotective
and neuromodulatory analgesic dipeptide (Tyr-Arg). Santos et al. reported that it has an inverse correlation with p-tau, and that p-tau/KTP values differ significantly between AD cases and controls [80] . Thus, KTP has potential utility in diagnosing AD. increase with aging in the healthy population, and they are increased in AD relative to healthy controls [81] , indicating that they have potential to serve as biomarkers of AD.
Oxidative Stress
F2-isoprostanes
Infl ammation
Chemokines Chemokines and chemokine receptors are up-regulated in brain cells during AD, contributing to plaque-associated inflammation and neurodegeneration.
The expression of CSF chemokine ligand 2 (CCL2), a member of the chemokine family that plays a significant role in infl ammatory processes, is increased in AD and is positively correlated with p-tau levels [82] . CCL2 may serve as a potential biomarker to monitor the progression of AD. (Aβ42, t-tau, and p-tau) [83] , suggesting potential as a biomarker for preclinical AD. dementias, and that CSF VILIP-1/Aβ42 predicts cognitive impairment as well as tau/Aβ42 and p-tau181/Aβ42 [84, 85] .
YKL-40
Other Potential Biomarkers
Dickkopf homolog 3 (Dkk-3) Dkk-3 is a novel potential biomarker for AD. Significantly elevated Dkk-3 levels in CSF were found in AD patients compared with healthy individuals but not in patients suffering from MCI or depression [86] , indicating that elevated Dkk-3 levels are specifi cally associated with AD.
Sphingomyelin (SM)
SM is one of the major phospholipid classes and increasing evidence demonstrates that lipids are critical in AD. SM levels in CSF of probable AD patients are higher than in controls [87] , indicating that SM could serve as a biomarker of AD.
Pigment epithelium-derived factor (PEDF), haptoglobin,
and tau PEDF and haptoglobin in CSF identified by proteomic analysis differ between healthy controls and AD patients. In combination with tau, PEDF and haptoglobin could improve the differential diagnosis of AD, especially in cases with moderate to severe dementia. PEDF, haptoglobin, and tau are potential markers for diagnosing AD [88] , while needing further investigation in larger population.
Heart-type fatty-acid-binding protein (hFABP) and vascular endothelial growth factor (VEGF) With proteomic techniques, the levels of hFABP and VEGF markedly differ between healthy controls and AD patients.
Combined with the three core biomarkers (Aβ42, t-tau, and p-tau), hFABP and VEGF can distinguish AD dementia from healthy controls with 83% sensitivity and 86% specificity.
hFABP also predicts the progression from MCI to AD dementia. The study by Guo et al. supports the potential of hFABP and VEGF in CSF as AD biomarkers in combination with Aβ42, t-tau, and p-tau181 [89] . precursor, Aβ, apolipoprotein E precursor, serum albumin precursor, keratin type I cytoskeletal 9, and tetranectin) was able to discriminate AD patients from controls with a median accuracy of 95% (sensitivity 85% and specificity 97%) [90] . [91] . that augment the core CSF biomarkers (Aβ42, t-tau, and p-tau) for distinguishing very mildly/mildly demented from cognitively normal individuals [92] . In addition, calbindin may be a novel biomarker. and a specifi city of 83%, while CSF Aβ42, t-tau, and p-tau diagnosed AD with a sensitivity of 88% and a specificity of 67% in the same sample [93] . Such specific peptide fi ngerprints may allow early differential diagnosis of various dementias and distinction of incipient AD from MCI.
CSF Proteomic Biomarkers of AD
Twelve-protein panel
Synaptic proteins
Conclusions and Perspectives
Although numerous studies have shown that the well- 
